Feb 25 (Reuters) - GE Healthcare Technologies Inc GEHC.O:
PATIENTS IN THE US UNDERGO FIRST DOSES OF GE HEALTHCARE’S NEW PET RADIOTRACER, FLYRCADO (FLURPIRIDAZ F 18) INJECTION
GE HEALTHCARE TECHNOLOGIES INC - FLYRCADO EXPECTED TO BE AVAILABLE AT MOST CARDIAC PET CENTERS BY 2025
GE HEALTHCARE TECHNOLOGIES INC - FULL COMMERCIALIZATION OF FLYRCADO ANTICIPATED IN Q2 2025
Source text: ID:nBw6WSqfsa
Further company coverage: GEHC.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.